# Metastatic Pancreatic Cancer: ASCO Guideline Update Study Guide This study guide provides a comprehensive overview of the 2020 focused update to the American Society of Clinical Oncology (ASCO) clinical practice guidelines for metastatic pancreatic cancer. It synthesizes current recommendations for initial assessment, first-line therapy, and the expanding role of precision medicine in second-line and maintenance treatments. --- ## I. Key Concepts and Summary ### 1. Epidemiology and Clinical Context * **Disease Burden:** In 2020, there were an estimated 57,600 new cases and 47,050 deaths due to pancreatic cancer in the United States. * **Prognosis:** Pancreatic ductal adenocarcinoma is characterized by early micrometastatic spread. The 5-year survival rate for metastatic disease is approximately 2.9%. * **Evolution of Guidelines:** The first ASCO guideline was published in 2016. Updates in 2018 and 2020 have focused on incorporating evidence for immunotherapy and targeted therapies. ### 2. Initial Assessment and Biomarker Testing The guideline emphasizes early and comprehensive assessment to facilitate timely treatment transitions. * **Imaging:** Multiphase CT scans of the chest, abdomen, and pelvis are the standard for staging. * **Genomic Testing (Recommendation 1.5):** Early testing for actionable alterations—including both germline and somatic (tumor) testing—is recommended for all potential candidates for second-line therapy. * **Primary Biomarkers:** * Microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR). * *BRCA1* and *BRCA2* mutations. * *NTRK* gene fusions. ### 3. First-Line Treatment Paradigms Treatment selection is primarily driven by the patient’s Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) and comorbidity profile. | Regimen | Patient Criteria | | :--- | :--- | | **FOLFIRINOX** | ECOG PS 0–1; favorable comorbidity profile; strong support system. | | **Gemcitabine + nab-paclitaxel** | ECOG PS 0–1; relatively favorable comorbidity profile. | | **Gemcitabine Alone** | ECOG PS 2 or comorbidities precluding aggressive therapy. | | **Optimized Supportive Care** | ECOG PS 3 or poorly controlled comorbid conditions. | ### 4. Precision Medicine and Second-Line Therapy The 2020 update introduced specific recommendations for targeted agents based on new clinical evidence. * **TRK Fusion Inhibitors (NTRK fusions):** Larotrectinib or entrectinib are recommended for patients with tumors harboring *NTRK* fusions. * **PARP Inhibitors (BRCA mutations):** Olaparib is a maintenance option for patients with germline *BRCA1/2* mutations who have achieved at least 16 weeks of stability on platinum-based chemotherapy. * **Immune Checkpoint Inhibitors (MSI-H/dMMR):** Pembrolizumab is recommended as second-line therapy for MSI-H or dMMR tumors. * **Cytotoxic Shifts:** * If FOLFIRINOX was used first: Gemcitabine + nab-paclitaxel. * If Gemcitabine-based therapy was used first: Fluorouracil + nanoliposomal irinotecan (preferred) or Fluorouracil + oxaliplatin. ### 5. Palliative Care and Communication * **Early Integration:** Palliative care assessment should occur at the first visit. It is distinct from hospice and can be part of an active treatment paradigm. * **Symptom Management:** Emphasis is placed on aggressive treatment of pain, fatigue, and dietary issues. * **Shared Decision-Making:** Clinicians must balance "realistic hope" with honest discussions regarding prognosis, the lack of overall survival (OS) benefit in certain maintenance trials (like POLO), and the potential for clinical trial participation. --- ## II. Short-Answer Practice Questions 1. **What is the recommended imaging modality for the initial staging of metastatic pancreatic cancer?** * *Answer:* A multiphase computed tomography (CT) scan of the chest, abdomen, and pelvis. 2. **Identify the three specific genomic alterations that the Expert Panel recommends testing for during the initial assessment.** * *Answer:* Microsatellite instability/mismatch repair deficiency (MSI/dMMR), *BRCA* mutations, and *NTRK* gene fusions. 3. **According to Recommendation 3.3, what are the two primary requirements for a patient to be eligible for maintenance therapy with olaparib?** * *Answer:* The patient must have a germline *BRCA1* or *BRCA2* mutation and must have received at least 16 weeks of first-line platinum-based chemotherapy without disease progression. 4. **What is the "LOXO-195" agent currently being researched for?** * *Answer:* It is a newer agent being studied to overcome resistance to first-generation TRK inhibitors. 5. **What is the significance of an ECOG Performance Status of 3 in treatment planning?** * *Answer:* Patients with a PS of 3 should only be offered cancer-directed therapy on a case-by-case basis, with the major emphasis on optimizing supportive care measures. 6. **Why does the guideline recommend against using CA19-9 as a substitute for imaging when assessing treatment response?** * *Answer:* CA19-9 is not considered an optimal substitute for imaging, which is the preferred method (specifically CT with contrast) to assess response every 2 to 3 months. 7. **What is the preferred second-line cytotoxic regimen for a patient who progressed on a gemcitabine-based first-line therapy?** * *Answer:* Fluorouracil plus nanoliposomal irinotecan (or fluorouracil plus irinotecan if the nanoliposomal version is unavailable). 8. **Define a "favorable comorbidity profile" regarding bilirubin and creatinine levels as per the guideline definitions.** * *Answer:* Bilirubin must be ≤ 1.5 times the upper limit of normal, and creatinine clearance must be ≥ 60 mL/min/1.73 m². 9. **Which two drugs are approved for patients with *NTRK* gene fusions regardless of the tumor site?** * *Answer:* Larotrectinib and entrectinib. 10. **In the POLO trial, did olaparib show a statistically significant benefit in Overall Survival (OS)?** * *Answer:* No; while it showed a significant improvement in Progression-Free Survival (PFS), there was no significant difference in OS compared to the placebo group at the time of the analysis. --- ## III. Essay Prompts for Deeper Exploration 1. **The Shift Toward Precision Medicine:** Discuss how the inclusion of "basket trials" (e.g., Drilon et al. and Doebele et al.) has influenced the ASCO guidelines for pancreatic cancer. Address the challenges of making recommendations based on low-prevalence biomarkers like *NTRK* fusions. 2. **Shared Decision-Making in Maintenance Therapy:** Using the qualifying statement for Recommendation 3.3, analyze the various factors an oncologist and a patient with a germline *BRCA* mutation must weigh when deciding between continuing chemotherapy or switching to olaparib maintenance. 3. **The Role of Palliative Care in Metastatic Disease:** Critique the common misconception that palliative care is synonymous with hospice. Explain how the ASCO guidelines integrate palliative assessment into the standard of care from the moment of diagnosis. 4. **Clinical Trial Integration:** The guideline states that "cancer clinical trials are vital to inform medical decisions." Evaluate the role of clinical trials in the current pancreatic cancer treatment landscape, specifically for patients who have exhausted first- and second-line cytotoxic options. --- ## IV. Glossary of Important Terms * **Actionable Genomic Alterations:** Genetic mutations or fusions in a tumor (somatic) or inherited (germline) that can be targeted by specific available drugs or clinical trials. * **Basket Trial:** A type of clinical trial that tests how well a new drug works in patients who have different types of cancer but share the same genetic mutation or biomarker. * **BRCA1/BRCA2:** Genes that produce proteins that help repair damaged DNA; mutations in these genes increase the risk of various cancers, including pancreatic cancer. * **dMMR (Mismatch Repair Deficiency):** A condition where a cell is unable to repair mistakes made when DNA is copied. * **ECOG Performance Status (PS):** A scale used by clinicians to assess how a patient's disease is progressing and how it affects their daily living abilities (0 = fully active; 4 = completely disabled). * **FOLFIRINOX:** A combination chemotherapy regimen consisting of leucovorin, fluorouracil, irinotecan, and oxaliplatin. * **MSI-H (Microsatellite Instability-High):** A biomarker indicating a high amount of genetic instability within a tumor, often making it susceptible to immunotherapy. * **NTRK (Neurotrophin Tyrosine Receptor Kinase) Fusion:** A genetic alteration where an *NTRK* gene joins with another gene, leading to uncontrolled cell growth. * **PARP Inhibitor:** A type of drug (like olaparib) that blocks an enzyme used by cells to repair DNA damage, particularly effective in cells with *BRCA* mutations. * **Platinum-Sensitive:** A term for tumors that respond to platinum-based chemotherapy (e.g., cisplatin or oxaliplatin). * **Progression-Free Survival (PFS):** The length of time during and after treatment that a patient lives with the disease, but it does not get worse. * **Somatic Testing:** Testing performed on tumor tissue to look for mutations acquired during a person's life, rather than inherited.